On Wednesday, Merck & Co Inc (NYSE:MRK) reported second-quarter sales of $16.1 billion, up 7% year-over-year, beating the consensus estimate of $15.84 billion. Excluding the impact of foreign exchange, sales increased 11%.
Merck reported adjusted EPS of $2.28, a shift from an EPS loss of $(2.06), beating the consensus of $2.15.
The pharmaceutical unit booked $14.41 billion in revenue, up 7% year over year. Growth in oncology, cardiovascular, and vaccines, partially offset by declines in diabetes and virology, drove the growth.
Also Read: Merck Gets Legal Victory As Appeals Court Dismisses Shingles Vaccine Some 1,200 Lawsuits.
Merck’s blockbuster cancer immunotherapy Keytruda generated $7.27 billion in revenue during the quarter, up …